Last reviewed · How we verify
NCT05491044
A Study of Orelabrutinib in CLL/SLL Patients Who Are Slowly Responding to Ibrutinib
Phase 2 trial testing orelabrutinib in CLL/SLL in 30 participants. Status unknown.
28 August 2024
Quick facts
| Lead sponsor | Peking University People's Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 January 2022 |
| Primary completion | 28 August 2024 |
| Estimated completion | 30 August 2024 |
| Sites | 2 locations across China |
Drugs / interventions tested
- orelabrutinib — full drug profile →
Conditions studied
- CLL/SLL — all drugs for CLL/SLL →
Sponsor
Peking University People's Hospital
Who can join
18 and older, any sex, with CLL/SLL. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single arm, multi-center study to evaluate the efficacy and safety of orelabrutinib for Chronic lymphocytic lymphoma（CLL)/small lymphocytic lymphoma (SLL) patients who are slowly responding to Ibrutinib switched to Orelabrutinib.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05491044
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of orelabrutinib
Trials testing the same drug.
- NCT06476899 — A Practical Clinical Study Comparing the Fixed-cycle Regimen Containing Orelabrutinib With BTKi Monotherapy · Phase 2 · not yet recruiting
- NCT04899427 — Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymph · Phase 2 · unknown
- NCT04711148 — A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis · Phase 2 · unknown
Other recruiting trials for CLL/SLL
Currently open trials in the same condition.
- NCT07108998 — Study of Epcoritamab as a Consolidation Therapy in CLL/SLL · Phase 2 · recruiting
- NCT06978088 — LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This · Phase 2 · recruiting
- NCT06508684 — Current Status of BTKi Treatment for CLL/SLL in China · recruiting
- NCT06104566 — Global Trial in APG2575 for Patients With CLL/SLL · Phase 3 · recruiting
- NCT05590702 — French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real-World Set · active not recruiting
Other Peking University People's Hospital trials
Trials by the same sponsor.
- NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
- NCT07516002 — Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency · not yet recruiting
- NCT07294339 — A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positiv · NA · not yet recruiting
- NCT07500441 — Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML · recruiting
- NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05491044 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University People's Hospital
- Last refreshed: 26 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05491044.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing